Cargando…

The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants

BACKGROUND AND OBJECTIVE: Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the second-line treatment of patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. Lorlatinib is metabolized by cytochrome P450 (CYP) 3A and contraindicated with strong...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jerry, Pithavala, Yazdi K., Gong, Jason, LaBadie, Robert R., Mfopou, Josué Kunjom, Chen, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505275/ https://www.ncbi.nlm.nih.gov/pubmed/33937953 http://dx.doi.org/10.1007/s40262-021-01026-w

Ejemplares similares

A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment
por: Lin, Swan, et al.
Publicado: (2022)

Correction to: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment
por: Lin, Swan, et al.
Publicado: (2022)

Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants
por: Xu, Huiping, et al.
Publicado: (2021)

Population pharmacokinetic model with time‐varying clearance for lorlatinib using pooled data from patients with non‐small cell lung cancer and healthy participants
por: Chen, Joseph, et al.
Publicado: (2021)

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
por: Hibma, Jennifer E., et al.
Publicado: (2021)

Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
por: Hibma, Jennifer E., et al.
Publicado: (2022)

Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single‐Dose, Matched Case‐Control Study
por: Masters, Joanna C., et al.
Publicado: (2020)

Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition
por: Sun, Steven, et al.
Publicado: (2022)

Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study
por: Chen, Joseph, et al.
Publicado: (2021)

Recent Advances and Prospects in the Differentiation of Pancreatic Cells From Human Embryonic Stem Cells
por: Mfopou, Josué Kunjom, et al.
Publicado: (2010)

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
por: Bauer, Todd M., et al.
Publicado: (2020)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers
por: Shaik, Naveed, et al.
Publicado: (2021)

Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
por: Shaik, Naveed, et al.
Publicado: (2018)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)

Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants
por: Perera, Vidya, et al.
Publicado: (2022)

Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
por: Humeniuk, Rita, et al.
Publicado: (2023)

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib
por: Piscitelli, Joseph, et al.
Publicado: (2022)

Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants
por: Peters, Erica N, et al.
Publicado: (2021)

Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants
por: Peters, Erica N, et al.
Publicado: (2021)

Modafinil in the treatment of excessive sleepiness
por: Schwartz, Jonathan RL
Publicado: (2009)

Fixed drug eruptions with modafinil
por: Ghoshal, Loknath, et al.
Publicado: (2015)

The underlying mechanisms of lorlatinib penetration across the blood‐brain barrier and the distribution characteristics of lorlatinib in the brain
por: Chen, Wei, et al.
Publicado: (2020)

Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
por: Suk, Yujin, et al.
Publicado: (2023)

Acute Effects of Modafinil on Brain Resting State Networks in Young Healthy Subjects
por: Esposito, Roberto, et al.
Publicado: (2013)

Modafinil-Induced Changes in Functional Connectivity in the Cortex and Cerebellum of Healthy Elderly Subjects
por: Punzi, Miriam, et al.
Publicado: (2017)

Absolute Oral Bioavailability of Glasdegib (PF‐04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers
por: Shaik, Naveed, et al.
Publicado: (2019)

Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants
por: Cheung, Tommy Tsang, et al.
Publicado: (2023)

Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study
por: Xie, Panpan, et al.
Publicado: (2023)

Participation of Dopamine D1 and D2 Receptors in the Rapid-Onset Behavioral Sensitization to Modafinil
por: Wuo-Silva, Raphael, et al.
Publicado: (2019)

Modafinil in the media: Metaphors, medicalisation and the body
por: Coveney, Catherine M., et al.
Publicado: (2009)

Modafinil modulation of the default mode network
por: Minzenberg, Michael J., et al.
Publicado: (2010)

Modafinil-induced Fixed Drug Eruption
por: Gaikwad, Girish Vasant, et al.
Publicado: (2012)

A rare case modafinil dependence
por: Krishnan, Raman, et al.
Publicado: (2015)

Pharmacokinetic Study and Tissue Distribution of Lorlatinib in Mouse Serum and Tissue Samples by Liquid Chromatography-Mass Spectrometry
por: Chen, Wei, et al.
Publicado: (2019)

Modafinil Induces Rapid-Onset Behavioral Sensitization and Cross-Sensitization with Cocaine in Mice: Implications for the Addictive Potential of Modafinil
por: Wuo-Silva, Raphael, et al.
Publicado: (2016)

Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers
por: Müller, U., et al.
Publicado: (2013)

Comparative Effects of Methylphenidate, Modafinil, and MDMA on Response Inhibition Neural Networks in Healthy Subjects
por: Schmidt, André, et al.
Publicado: (2017)

A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK‐041 in healthy participants and patients with stable schizophrenia
por: Yin, Wei, et al.
Publicado: (2022)

Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants
por: Barth, Aline, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3ujmngbo6rip1687bth78e8tcq